Posted by Michael Wonder on 27 Jul 2023
Soliris approved in the EU for children and adolescents with refractory generalised myasthenia gravis
27 July 2023 - First and only targeted therapy approved for paediatric patients with generalised myasthenia gravis in the EU showed sustained improvements in disease severity and function over 26 weeks.
Soliris (eculizumab) has been approved in the European Union for expanded use to include the treatment of refractory generalised myasthenia gravis in children and adolescents aged six to 17 years who are anti-acetylcholine receptor antibody positive.
